North America Virology Market

Market Introduction

The North America virology market is analyzed based on three major countries: the US, Canada, and Mexico. The US holds the largest size of the virology market owing to factors such as the increasing burden of COVID19, increasing product launches are among the factors leading the market. In North America, the US is the largest market for virology solutions. The growth of the US market is primarily driven by increasing research and development activities and rising demand for advanced diagnostic solutions to treat chronic conditions and viral diseases. In addition, increasing demand for viral antigens due to the growing adoption of advances viral testing is also anticipated to drive the market during the forecast period. Due to the increasing demand, major players in the market are focusing on expanding their viral antigens manufacturing capacity. The pharmaceutical and biotechnology companies in the country are actively operating to develop effective vaccines for COVID19. Various players have received EUA for respective vaccines. The data is being studied continuously on a larger scale, and the drug manufacturers are consistently developing antiviral drugs for COVID19. However, despite the commercialization and widespread access to vaccines, the primary focus is still to perform maximum testing for COVID19 to control the infection rate. For instance, in May 2020, the US FDA approved emergency use authorization for a COVID19 antigen test from Quidel Corporation for the Sofia 2 SARS Antigen FIA. Thus, similar approvals by the regulatory agencies are expected to support the growth of the virology market. Rise in prevalence of viral infectious diseases is the major factor driving the growth of the North America virology market.

North America has experienced a rising number of cases of COVID-19 since its outbreak. The cases are also increasing in countries such as Mexico and Canada in the region. As COVID19 is a novel virus and had no established treatment methods, no vaccines, drugs specific to the virus were not available. Thus, it was a potential opportunity for product innovation and development to the market players operating in the virology-related business. The governments have extensively invested in and promoted vaccine development and prioritized the easy and quick approval process. Regional and international players launch various virus products such as rapid test kits, vaccines, and others. And the large-scale production of these products and rising demand are expected to have a favorable impact on the virology-related market in the region. However, the end-users' panic buying and stocking of the products are expected to cause a loss in terms of product expiry. Thus, such factors are expected to have a negative impact on the related market in the region.

Market Overview and Dynamics

The virology market in North America is expected to grow from US$ 1,531.21 million in 2021 to US$ 1,984.33 million by 2028; it is estimated to grow at a CAGR of 3.8% from 2021 to 2028. Countries such as Mexico are attractive outsourcing locations for the pharmaceutical and biopharmaceutical industries across the region. Low manufacturing and operating costs and recent growth in the pharmaceutical industry in Mexico are key factors driving the growth of the virology-related markets in this country. Moreover, the growing domestic market and its pipelines are opening new access for the manufacturing of generic drugs in the region. In addition, several contract-based organizations are expanding their manufacturing capacities in North American nations to meet the rising demand for products, such as vaccines. Thus, the emerging markets are likely to create lucrative opportunities for the growth of the virology market in the coming years across the North America region.

Key Market Segments

The North America virology market is segmented on the bases of type, application, end user, and country. Based on type, the market is segmented into diagnostic test, viral infection controlling techniques, antiviral therapeutics, and interferons. The antiviral therapeutics segment dominated the market in 2020 and viral infection controlling techniques segment is expected to be the fastest growing during the forecast period. The diagnostic test segment is further categorized into DNA virus testing, RNA virus testing, others. Similarly, the viral infection controlling techniques is bifurcated into active prophylaxis, and passive prophylaxis. Likewise, the antiviral therapeutics segment is categorized into virucidal agents, antiviral agents, immunomodulators, and interferons. On the basis of application, the virology market is segmented into skin and soft tissue infections, respiratory tract infections, GI tract infections, sexually transmitted diseases, urinary tract infections, and others. The respiratory tract infections segment dominated the market in 2020, and is expected to be the fastest growing during the forecast period. On the basis of end user, the virology market is segmented into hospitals, diagnostic laboratories, pharmaceutical and biotechnological companies, and research and academic institutes. The hospitals segment dominated the market in 2020, and diagnostic laboratories segment is expected to be the fastest growing during the forecast period.

Major Sources and Companies Listed

A few major primary and secondary sources referred to for preparing this report on the virology market in North America are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Abbott; AbbVie Inc.; F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; GlaxoSmithKline Plc; Illumina, Inc.; Johnson and Johnson Services, Inc.; QIAGEN; Siemens AG; and Thermo Fisher Scientific Inc. are among others.

Reasons to buy report

• To understand the North America virology market landscape and identify market segments that are most likely to guarantee a strong return
• Stay ahead of the race by comprehending the ever-changing competitive landscape for North America virology market
• Efficiently plan M&A and partnership deals in North America virology market by identifying market segments with the most promising probable sales  
• Helps to take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segment form North America virology market
• Obtain market revenue forecast for market by various segments from 2021-2028 in North America region.

North America Virology Market Segmentation

North America Virology Market -By Type

• Diagnostic Test
  • DNA Virus Testing
  • RNA Virus Testing
  • Others
• Viral Infection Controlling Techniques
  • Active Prophylaxis
  • Passive Prophylaxis
• Antiviral Therapeutics
  • Virucidal Agents
  • Antiviral Agents
  • Immunomodulators
• Interferons

North America Virology Market -By Application

• Skin and Soft Tissue Infections
• Respiratory Tract Infections
• GI Tract Infections
• Sexually Transmitted Diseases
• Urinary Tract Infections
• Others

North America Virology Market -By End User

• Hospitals
• Diagnostic Laboratories
• Pharmaceutical and Biotechnological Companies
• Research and Academic Institutes

North America Virology Market -By Country

• US
• Canada
• Mexico

North America Virology Market -Company Profiles

• Abbott
• AbbVie Inc.
• . F. Hoffmann-La Roche Ltd.
• Gilead Sciences, Inc.
• GlaxoSmithKline Plc
• Illumina, Inc.
• Johnson and Johnson Services, Inc.
• QIAGEN
• Siemens AG
• Thermo Fisher Scientific Inc.

North America Virology Market Strategic Insights

North America VirologyMarket Report Highlights

North America Virology Market Country and Regional Insights